Clinical trials: Conjunctivitis, Allergic
Vernal Keratoconjunctivitis
Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
The objective of this study is to compare the efficacy of two different dosing regimen of NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of the formulation) administered four times a day…
- Trial name
- NCT01751126
- Testing
- NOVA22007 ''Ciclosporin''
- Where
- 46 sites in United States, Croatia and 9 more
- Volunteers
- 169 people
- Sponsor
- Santen SAS
Allergic Conjunctivitis
A Six-Week Safety Study of an Investigational Ophthalmic Solution
The purpose of this study was to evaluate the ocular safety of an investigational ophthalmic solution in subjects 2 years of age and older with asymptomatic eyes when administered once daily in both eyes for up to 6 weeks.
- Trial name
- NCT01698814
- Testing
- AL-4943A Ophthalmic Solution, AL-4943A Ophthalmic Solution Vehicle
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Allergic Conjunctivitis
An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis
The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.
- Trial name
- NCT01037179
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
- Where
- Japan
- Volunteers
- 110 people
- Sponsor
- Alcon Research
Keratoconjunctivitis, Vernal
Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis
To assess the clinical and biological efficacity of preservative free NAAGA eyes drops in vernal keratoconjunctivitis
- Trial name
- NCT00357019
- Testing
- N-acetyl-aspartyl-glutamate (NAAXIA Sine)
- Sponsor
- Laboratoires Thea
Conjunctivitis, Allergic
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
- Trial name
- NCT00424398
- Testing
- Bepreve, Bepotastine Besilate
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Bausch & Lomb Incorporated
Conjunctivitis, Allergic
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT01732757
- Testing
- Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Allergan
Allergic Conjunctivitis
Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
The purpose of this study is to study the safety and efficacy of bepotastine besilate ophthalmic solution in allergic conjunctivitis patients.
- Trial name
- NCT01174823
- Testing
- bepotastine besilate ophthalmic solution
- Where
- United States
- Volunteers
- 245 people
- Sponsor
- Bausch & Lomb Incorporated
Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic
Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract of Phleum pratense in the rhinoconjunctivitis and/or asthma of slight or moderate…
- Conditions
- Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic, Asthma
- Trial name
- NCT00501527
- Testing
- Immunotherapy with modified extract of P. pratense pollen
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Laboratorios Leti, S.L.
Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis
Tyrosine Allergoid Paediatric and Adult Study
The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial…
- Conditions
- Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis, Allergic Asthma
- Trial name
- NCT05186025
- Testing
- MATA trees or MATA grass
- Where
- Germany
- Volunteers
- 320 people
- Sponsor
- Allergy Therapeutics
Allergic Conjunctivitis
Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients
The objective of this study is to further evaluate the safety of Olopatadine Ophthalmic Solution 0.1% in Japanese children with allergic conjunctivitis.
- Trial name
- NCT01109485
- Testing
- Olopatadine hydrochloride ophthalmic solution 0.1%
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis, Allergic Rhinitis
Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections
A safety study conducted on subjects ≥16 years old evaluating the safety of 4 intralymphatic injections of 2 different dose levels of the investigational short and tall ragweed product.
- Trial name
- NCT03038971
- Testing
- Dose Level 1, Dose Level 2
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Woodmont Pharmaceuticals, Inc.
Allergic Conjunctivitis
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT02322216
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle
- Volunteers
- 383 people
- Sponsor
- Alcon Research
Keratoconjunctivitis, Conjunctivitis
Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
To investigate the efficacy and safety of FK506 ophthalmic suspension on eye symptoms in patients with vernal keratoconjunctivitis
- Trial name
- NCT00567762
- Testing
- FK506
- Where
- 8 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Astellas Pharma Inc
Atopic Conjunctivitis
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye).
- Trial name
- NCT00884585
- Testing
- Cyclosporine Vehicle, Cyclosporine 0.010%
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 176 people
- Sponsor
- Allergan
Seasonal Allergic Conjunctivitis
Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis
Medications available for the treatment of seasonal allergic conjunctivitis include antihistamines. These medicines block the release of histamine, a substance in the body that is released when an allergic reaction occurs.
- Trial name
- NCT00133627
- Testing
- Ketotifen
- Where
- China
- Volunteers
- 229 people
- Sponsor
- Novartis
Conjunctivitis, Allergic
Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
This post-marketing surveillance study will assess the safety and efficacy of Lastacaft® Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of…
- Trial name
- NCT02555761
- Testing
- Alcaftadine Ophthalmic Solution 0.25%
- Where
- 81 sites in South Korea
- Volunteers
- 3,423 people
- Sponsor
- Allergan
Allergic Conjunctivitis
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy drug with a contact lens compared to placebo in preventing ocular itching associated with allergic conjunctivitis
- Trial name
- NCT00445874
- Testing
- Ketotifen with a Contact Lens (no generic name)
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vistakon Pharmaceuticals
Conjunctivitis, Allergic
AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.
- Trial name
- NCT02082262
- Testing
- AGN-229666
- Where
- Japan
- Volunteers
- 140 people
- Sponsor
- Allergan
Allergic Conjunctivitis
A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis
This study will evaluate the safety and efficacy of a new allergy medication
- Trial name
- NCT00375596
- Testing
- Ketotifen/vasoconstrictor
- Sponsor
- Bausch & Lomb Incorporated
Conjunctivitis, Allergic
OJO-miR: microRNA Expression in Allergic Conjunctivitis.
Allergic conjunctivitis (AC) causes inflammation of the conjunctiva in response to environmental allergens, affecting a significant percentage of the world population and reducing quality of life.
- Trial name
- OJO-miR (NCT07385495)
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana